 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | ADEL-Y01 / Oscotec, ADEL
Trial completion date: A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 (clinicaltrials.gov) - Oct 23, 2024
P1, N=73, Recruiting, Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc.
Trial completion date: May 2026 --> Feb 2026
- ADEL-Y01 / Oscotec, ADEL
Preclinical efficacy and rationale of targeting lysine280-acetylated tau for Alzheimer (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_3661;
Based on our observations that tau-acK280 is a core species involved in seeding and propagation activities, the Y01 antibody that specifically recognizes acK280 represents a promising therapeutic candidate for AD and other neurodegenerative diseases associated with tauopathy. ADEL-Y01 is currently undergoing a phase-1 clinical trial in the United States through a collaborative effort between ADEL and Oscotec.
- ||| ADEL-Y01 / Oscotec, ADEL
Enrollment open: A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 (clinicaltrials.gov) - Feb 13, 2024
P1, N=73, Recruiting, Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc.
ADEL-Y01 is currently undergoing a phase-1 clinical trial in the United States through a collaborative effort between ADEL and Oscotec. Not yet recruiting --> Recruiting
- ||| ADEL-Y01 / Oscotec, ADEL
New P1 trial: A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 (clinicaltrials.gov) - Feb 7, 2024
P1, N=73, Not yet recruiting, Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc.